Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
171 hedge funds and large institutions have $339M invested in Antares Pharma, Inc. in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 47 reducing their positions, and 24 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 47
17% more capital invested
Capital invested by funds: $291M → $339M (+$48.3M)
10% more call options, than puts
Call options by funds: $1.18M | Put options by funds: $1.07M
8% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 24
2% less funds holding
Funds holding: 174 → 171 (-3)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$22.3M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$5.09M |
| 3 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$4.89M |
| 4 |
Morgan Stanley
New York
|
+$4.32M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$6.86M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.67M |
| 3 |
Goldman Sachs
New York
|
-$2.25M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$2.04M |
| 5 |
SAM
Silvercrest Asset Management
New York
|
-$1.06M |
ATRS Hedge Fund Activity: Q1 2021 in Review
171 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2021, worth a combined $339M — up 17% from $291M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ATRS and 22 opened new positions — a net loss of 2 holders — while 47 trimmed existing stakes and 55 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $22.3M. The largest seller was HealthInvest Partners, exiting entirely with an estimated $6.86M sold.
- 171 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2021, down from 174 in Q4 2020.
- Funds reported $339M of Antares Pharma, Inc. stock for Q1 2021, up 17% quarter-over-quarter.
- 22 funds opened new Antares Pharma, Inc. positions in Q1 2021 and 24 closed out, a net change of -2 holders.
- The largest Antares Pharma, Inc. buyer in Q1 2021 was Rubric Capital Management (New York), an estimated $22.3M added.
- The largest Antares Pharma, Inc. seller in Q1 2021 was HealthInvest Partners, an estimated $6.86M sold.
Based on aggregated 13F filings for Q1 2021.